Clinical trials: Manganese Safety in Adults
Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis.
- Conditions
- Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign
- Trial name
- NCT06322342
- Testing
- RVP-001
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Reveal Pharmaceuticals Inc.
Manganese Safety in Adults
Tralement Versus a Fixed-dose Trace Element Combination Product to Evaluate Manganese Safety
Tralement versus a fixed-dose trace element combination product of zinc, copper, and selenious acid to evaluate product safety in adult patients requiring long-term parenteral nutrition.
- Trial name
- NCT05661682
- Testing
- Tralement, Fixed-dose trace element combination product of zinc, copper, and selenious acid
- Sponsor
- American Regent, Inc.
Healthy
First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent
The objectives of this trial are: 1. To evaluate the safety and tolerability of single ascending doses of RVP-001 in healthy adult volunteers 2.
- Trial name
- NCT05413668
- Testing
- RVP-001
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Reveal Pharmaceuticals Inc.